Exenatide in clinic for reperfusion injury
Links shared publicly online about this topic.
- 2,286total visits
Exenatide in clinic for reperfusion injury
View full resource at theheart.org
Tags: Diabetes Type 2 Medication, Diabetes Medication, Drug, Clinical Trial, Byetta
Most Recently Shared on February 2, 2009 at 11:03 pm By:
Exenatide in clinical trials for reperfusion injury http://tinyurl.com/ba6frv
Trophos awarded US patent covering use of novel cardioprotective compound
news-medical.net — “Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes sign” View full resource at news-medical.net
Most Recently Shared on August 23, 2011 at 8:52 pm By:
Trophos awarded US patent covering use of novel cardioprotective compound: Trophos SA a clinical stage pharmaceu... http://t.co/UiqoUjH
Clinics - Effects of Urtica dioica on hepatic ischemia-reperfusion injury in rats
scielo.br — “Clinics - Effects of Urtica dioica on hepatic ischemia-reperfusion injury in rats” View full resource at scielo.br
Most Recently Shared on February 20, 2011 at 7:45 am By:
Urology & Nephrology OW Health
Effects of Urtica dioica on hepatic ischemia-reperfusion injury in rats: CONCLUSIONS: Urtica dioica has a protec... http://bit.ly/fX9uOd
Trophos Initiates Clinical Development For Novel Cardioprotective Compound, TRO40303 - QualityPoint Technologies
qualitypointtech.net — “Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced the initiation of clinical development for TRO40303, a novel mitochondria pore modulator. TRO40303 could become the first treatment to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen post myocardial infarction (MI)...” View full resource at qualitypointtech.net
Most Recently Shared on September 29, 2010 at 12:48 pm By:
Trophos Initiates Clinical Development For Novel Cardioprotective Compound, TRO40303: Trophos SA a clinical stage ... http://bit.ly/9aw3M4
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: Effect of exenatide Vaghasiya JD, Sheth NR, Bhalodia YS, Jivani NP - Saudi J Gastroenterol
saudijgastro.com — “Official Journal of Saudi Gastroenterology Association.” View full resource at saudijgastro.com
Most Recently Shared on July 8, 2010 at 10:46 am By:
Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: Effect of exenatide: Conclusion: Exena... http://bit.ly/bK9lPp
Ischemix Initiates Phase 2a Trial Of CMX-2043 For The Prevention Of Ischemia-Reperfusion Injury
medicalnewstoday.com — “Ischemix announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing e” View full resource at medicalnewstoday.com
Most Recently Shared on March 11, 2010 at 1:12 pm By:
MNT Cardiovascular Health News
Ischemix Initiates Phase 2a Trial Of CMX-2043 For The Prevention Of Ischemia-Reperfusion Injury http://mnt.to/3yLm #cardiovascular
Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury
news-medical.net — “Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.” View full resource at news-medical.net
Most Recently Shared on March 9, 2010 at 3:28 pm By:
Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury: Ischemix ... http://bit.ly/d6unbz
Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development
news-medical.net — “Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical precondi” View full resource at news-medical.net
Most Recently Shared on January 27, 2010 at 10:53 am By:
Stroke News: Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Deve... http://twurl.nl/4vmyuw
Advertisement
